These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15081035

  • 21. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.
    Williams TM, Stump CA, Nguyen DN, Quigley AG, Bell IM, Gallicchio SN, Zartman CB, Wan BL, Penna KD, Kunapuli P, Kane SA, Koblan KS, Mosser SD, Rutledge RZ, Salvatore C, Fay JF, Vacca JP, Graham SL.
    Bioorg Med Chem Lett; 2006 May 15; 16(10):2595-8. PubMed ID: 16527483
    [Abstract] [Full Text] [Related]

  • 22. Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
    Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.
    Bioorg Med Chem; 2008 Dec 01; 16(23):9991-10000. PubMed ID: 18952443
    [Abstract] [Full Text] [Related]

  • 23. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1795-8. PubMed ID: 16434195
    [Abstract] [Full Text] [Related]

  • 24. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.
    Wu WL, Burnett DA, Spring R, Greenlee WJ, Smith M, Favreau L, Fawzi A, Zhang H, Lachowicz JE.
    J Med Chem; 2005 Feb 10; 48(3):680-93. PubMed ID: 15689153
    [Abstract] [Full Text] [Related]

  • 25. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX, Chang LL, Truong Q, Doherty GA, Magriotis PA, de Laszlo SE, Li B, MacCoss M, Kidambi U, Egger LA, McCauley E, Van Riper G, Mumford RA, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Jun 03; 12(11):1497-500. PubMed ID: 12031328
    [Abstract] [Full Text] [Related]

  • 26. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
    Saku O, Ohta K, Arai E, Nomoto Y, Miura H, Nakamura H, Fuse E, Nakasato Y.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1053-7. PubMed ID: 18160288
    [Abstract] [Full Text] [Related]

  • 27. 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
    Hoshina Y, Ikegami S, Okuyama A, Fukui H, Inoguchi K, Maruyama T, Fujimoto K, Matsumura Y, Aoyama A, Harada T, Tanaka H, Nakamura T.
    Bioorg Med Chem Lett; 2005 Jan 03; 15(1):217-20. PubMed ID: 15582442
    [Abstract] [Full Text] [Related]

  • 28. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F, Rohatagi S, Pino M, DeLise B, Zhang J, Nguyen M, Guittin P, Barbellion S, Brunel P, Hofmann T, Schmidt J, Wong M, Lockey P, Lerman S, Clark R.
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr 03; 71(2):69-79. PubMed ID: 15098200
    [Abstract] [Full Text] [Related]

  • 29. Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.
    Huryn DM, Ashwell S, Baudy R, Dressen DB, Gallaway W, Grant FS, Konradi A, Ley RW, Petusky S, Pleiss MA, Sarantakis D, Semko CM, Sherman MM, Tio C, Zhang L.
    Bioorg Med Chem Lett; 2004 Apr 05; 14(7):1651-4. PubMed ID: 15026043
    [Abstract] [Full Text] [Related]

  • 30. Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
    Doherty GA, Yang GX, Borges E, Chang LL, MacCoss M, Tong S, Kidambi U, Egger LA, McCauley E, Van Riper G, Mumford RA, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Jun 03; 12(11):1501-5. PubMed ID: 12031329
    [Abstract] [Full Text] [Related]

  • 31. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
    Reger TS, Zunic J, Stock N, Wang B, Smith ND, Munoz B, Green MD, Gardner MF, James JP, Chen W, Alves K, Si Q, Treonze KM, Lingham RB, Mumford RA.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1173-6. PubMed ID: 20022493
    [Abstract] [Full Text] [Related]

  • 32. Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
    Kopka IE, Lin LS, Mumford RA, Lanza T, Magriotis PA, Young D, DeLaszlo SE, MacCoss M, Mills SG, Van Riper G, McCauley E, Lyons K, Vincent S, Egger LA, Kidambi U, Stearns R, Colletti A, Teffera Y, Tong S, Owens K, Levorse D, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Sep 02; 12(17):2415-8. PubMed ID: 12161146
    [Abstract] [Full Text] [Related]

  • 33. Highly potent, water soluble benzimidazole antagonist for activated alpha 4 beta 1 integrin.
    Carpenter RD, Andrei M, Lau EY, Lightstone FC, Liu R, Lam KS, Kurth MJ.
    J Med Chem; 2007 Nov 15; 50(23):5863-7. PubMed ID: 17948981
    [Abstract] [Full Text] [Related]

  • 34. Insights into phenylalanine derivatives recognition of VLA-4 integrin: from a pharmacophoric study to 3D-QSAR and molecular docking analyses.
    Macchiarulo A, Costantino G, Meniconi M, Pleban K, Ecker G, Bellocchi D, Pellicciari R.
    J Chem Inf Comput Sci; 2004 Nov 15; 44(5):1829-39. PubMed ID: 15446843
    [Abstract] [Full Text] [Related]

  • 35. Efficient synthesis of 3-aminocyclobut-2-en-1-ones: squaramide surrogates as potent VLA-4 antagonists.
    Brand S, de Candole BC, Brown JA.
    Org Lett; 2003 Jun 26; 5(13):2343-6. PubMed ID: 12816444
    [Abstract] [Full Text] [Related]

  • 36. The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
    Bell IM, Bednar RA, Corcoran HA, Fay JF, Gallicchio SN, Johnston VK, Hershey JC, Miller-Stein CM, Moore EL, Mosser SD, Roller SA, Salvatore CA, Theberge CR, Wong BK, Blair Zartman C, Kane SA, Williams TM, Graham SL, Vacca JP.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4740-2. PubMed ID: 19577468
    [Abstract] [Full Text] [Related]

  • 37. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
    Kopka IE, Young DN, Lin LS, Mumford RA, Magriotis PA, MacCoss M, Mills SG, Van Riper G, McCauley E, Egger LE, Kidambi U, Schmidt JA, Lyons K, Stearns R, Vincent S, Colletti A, Wang Z, Tong S, Wang J, Zheng S, Owens K, Levorse D, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Feb 25; 12(4):637-40. PubMed ID: 11844689
    [Abstract] [Full Text] [Related]

  • 38. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
    Tilley JW, Sidduri A, Lou J, Kaplan G, Tare N, Cavallo G, Frank K, Pamidimukkala A, Choi DS, Gerber L, Railkar A, Renzetti L.
    Bioorg Med Chem Lett; 2013 Feb 15; 23(4):1036-40. PubMed ID: 23312471
    [Abstract] [Full Text] [Related]

  • 39. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
    Kamenecka TM, Lanza T, de Laszlo SE, Li B, McCauley ED, Van Riper G, Egger LA, Kidambi U, Mumford RA, Tong S, MacCoss M, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Aug 19; 12(16):2205-8. PubMed ID: 12127538
    [Abstract] [Full Text] [Related]

  • 40. Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
    Sidduri A, Tilley JW, Lou J, Tare N, Cavallo G, Frank K, Pamidimukkala A, Choi DS, Gerber L, Railkar A, Renzetti L.
    Bioorg Med Chem Lett; 2013 Feb 15; 23(4):1026-31. PubMed ID: 23312474
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.